Correction to: Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXT.


Journal

Arthritis research & therapy
ISSN: 1478-6362
Titre abrégé: Arthritis Res Ther
Pays: England
ID NLM: 101154438

Informations de publication

Date de publication:
09 06 2020
Historique:
entrez: 11 6 2020
pubmed: 11 6 2020
medline: 11 6 2020
Statut: epublish

Résumé

An amendment to this paper has been published and can be accessed via the original article.

Identifiants

pubmed: 32517782
doi: 10.1186/s13075-020-02238-4
pii: 10.1186/s13075-020-02238-4
pmc: PMC7282066
doi:

Types de publication

Journal Article Published Erratum

Langues

eng

Sous-ensembles de citation

IM

Pagination

137

Commentaires et corrections

Type : ErratumFor

Références

Arthritis Res Ther. 2019 Dec 9;21(1):272
pubmed: 31815649

Auteurs

Vibeke Strand (V)

Stanford University, Palo Alto, CA, USA.

Janet Pope (J)

University of Western Ontario, London, ON, Canada.

Namita Tundia (N)

AbbVie Inc., North Chicago, IL, USA. namita.tundia@abbvie.com.

Alan Friedman (A)

AbbVie Inc., North Chicago, IL, USA.

Heidi S Camp (HS)

AbbVie Inc., North Chicago, IL, USA.

Aileen Pangan (A)

AbbVie Inc., North Chicago, IL, USA.

Arijit Ganguli (A)

AbbVie Inc., North Chicago, IL, USA.

Mahesh Fuldeore (M)

AbbVie Inc., North Chicago, IL, USA.

Debbie Goldschmidt (D)

Analysis Group, Inc., New York, NY, USA.

Michael Schiff (M)

University of Colorado, Denver, CO, USA.

Classifications MeSH